The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | Future perspectives in CAR-T therapy
Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, outlines recent developments in the field of chimeric antigen receptor T-cell (CAR-T) therapy. Despite the efficacy of CAR-Ts, many patients still relapse. Therefore, there have been efforts to improve our understanding of the biology of CAR-Ts and ameliorate their design, with advances in dual-targeting CAR-Ts for example. Dr Loschi also talks on CAR-transduced natural killer (NK) cells and allogeneic CAR-Ts, and highlights advances in CAR-Ts in new indications such as multiple myeloma, chronic lymphocytic leukemia (CLL), and T-cell malignancies, which are tumors with substantial unmet clinical needs. Moving forward, Dr Loschi comments on European CAR-T initiatives such as the CARAMBA project. Finally, he mentions remarkable advances in the development of CAR-Ts for solid tumors and interesting studies on the development of immunomodulation following CAR-T therapy. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
